Compositions and methods for targeted therapeutic delivery to bone

Abstract

Provided herein are polypeptides that constitute therapeutic agents for targeted delivery to organs or tissues, and uses thereof, particularly compositions and methods for targeted therapeutic delivery to bone.

Description

[0001] This application is a divisional application of Chinese patent application No. 202180042758.X, entitled "Composition and Method for Targeted Therapeutic Delivery to Bone" (the corresponding PCT application was filed on April 14, 2021, with application number PCT / US2021 / 027230). Technical Field

[0002] Priority requirements This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 010,639, filed April 15, 2020, which is incorporated herein by reference in its entirety.

[0003] sequence list This application contains a sequence list submitted electronically in ASCII format and incorporated herein in its entirety by reference. The ASCII copy was created on April 13, 2021, named 50222-705_601_SL.txt, and is 650,053 bytes in size. Background Technology

[0004] In the United States, an average of 6 million people suffer fractures each year. Most of these bone defects heal without problems. However, 5-10% of patients heal poorly or not at all (American Academy of Orthopaedic Surgeons). Large defects, also known as critical-size defects, may not heal spontaneously and can lead to nonunion. Nonunion occurs when there are no signs of healing for at least three months and no further healing is expected (American Academy of Orthopaedic Surgeons). Currently, bone grafting is considered the "gold standard" for treating large or segmental bone defects. However, this treatment has limitations, such as donor site pain, rejection risk, limited donor supply, and the risk of transmitting infectious diseases.

[0005] Repair of critical and complex bone and cartilage defects is also limited by poor tissue regeneration on the implanted orthopedic substrate. Causes of poor tissue regeneration include loss of implanted progenitor cells within 48 hours post-implantation and insufficient progenitor cell production. Another contributing factor is that current orthopedic substrates are unable to promote adequate tissue regeneration. Summary of the Invention

[0006] This disclosure is based on the finding that compositions comprising mammalian growth factors (e.g., bone morphogenetic protein 2 (BMP-2)) or their functional portions and targeting peptides (e.g., peptides bound to bone or carrier materials) can significantly improve bone healing and accelerate tissue regeneration. In a non-limiting embodiment, the targeting peptide is bound to a carrier material, such as calcium phosphate (e.g., β-tricalcium phosphate or β-TCP), hydroxyapatite, or other materials suitable for implantable devices. Therefore, this document provides: chimeric peptides comprising one or more targeting peptides and mammalian growth factors; compositions comprising any of these chimeric peptides (and optionally, carrier materials); and methods for promoting bone or cartilage formation, methods for replacing and / or repairing bone or cartilage, and methods for treating fractures or bone loss, including the administration of any of these compositions. The compositions and methods provided herein can increase and maintain the number of progenitor cells at the site of bone and / or cartilage injury through stem cell capture. The compositions and methods provided herein can also be applied to soft tissue repair or local delivery of therapeutic agents.

[0007] This document provides a polypeptide composition comprising: a targeting polypeptide comprising a sequence having at least 80% identity with SEQ ID NO: 22 (LLADTTHHRPWT VIGESTHHRPWS IIGESSHHKPFT GLGDTTHHRPWG ILAESTHHKPWT); and a therapeutic polypeptide comprising a sequence having at least 80% identity with a sequence selected from SEQ ID NO: 32, 46-71, 73-77, 79-101, 152, 168, 176, 268. In some embodiments, the therapeutic polypeptide comprises a sequence having at least 90% identity with a sequence selected from SEQ ID NO: 32, 46-71, 73-77, 79-101, 152, 168, 176, 268. In some embodiments, the therapeutic polypeptide comprises a sequence selected from SEQ ID NO: 32, 46-71, 73-77, 79-101, 152, 168, 176, 268. In some embodiments, the therapeutic peptide comprises a sequence having at least 80%, 85%, 90%, or 95% identity with SEQ ID NO: 32. In some embodiments, the therapeutic peptide comprises SEQ ID NO: 32. In some embodiments, the targeting peptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 22. In some embodiments, the targeting peptide comprises SEQ ID NO: 22. In some embodiments, the targeting peptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 22. In some embodiments, the targeting peptide comprises SEQ ID NO: 22. In some embodiments, the targeting peptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 22. In some embodiments, the targeting peptide comprises SEQ ID NO: 22. In some embodiments, the targeting peptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 22. In some embodiments, the targeting peptide comprises SEQ ID NO: 22. In some embodiments, the targeting peptide comprises a sequence having at least 90% or 95% identity with SEQ ID NO: 22. In some embodiments, the targeting peptide comprises SEQ ID NO: 22.

[0008] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 551 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 22 (LLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWT). In some embodiments, the composition comprises a sequence having at least about 90% or 95% identity with SEQ ID NO: 551.

[0009] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 639 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 2 (VIGESTHHRPWS). In some embodiments, the composition comprises a sequence having at least about 90% or 95% identity with SEQ ID NO: 639.

[0010] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 519 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 6 (IIGESSHHKPFT). In some embodiments, the composition comprises a sequence having at least about 90% or 95% identity with SEQ ID NO: 519.

[0011] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 521 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 7 (GLGDTTHHRPWG). In some embodiments, the composition comprises a sequence having at least about 90% or 95% identity with SEQ ID NO: 521.

[0012] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 515 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 4 (ILAESTHHKPWT). In some embodiments, the composition comprises a sequence having at least about 90% or 95% identity with SEQ ID NO: 515.

[0013] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 501. In some embodiments, the sequence has at least about 90% or 95% identity with SEQ ID NO: 501. In some embodiments, the sequence comprises SEQ ID NO: 501.

[0014] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 507. In some embodiments, the sequence has at least about 90% or 95% identity with SEQ ID NO: 507. In some embodiments, the sequence comprises SEQ ID NO: 507.

[0015] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 506. In some embodiments, the sequence has at least about 90% or 95% identity with SEQ ID NO: 506. In some embodiments, the sequence comprises SEQ ID NO: 506.

[0016] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 505. In some embodiments, the sequence has at least about 90% or 95% identity with SEQ ID NO: 505. In some embodiments, the sequence comprises SEQ ID NO: 505.

[0017] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 504. In some embodiments, the sequence has at least about 90% or 95% identity with SEQ ID NO: 504. In some embodiments, the sequence comprises SEQ ID NO: 504.

[0018] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 503. In some embodiments, the sequence has at least about 90% or 95% identity with SEQ ID NO: 503. In some embodiments, the sequence comprises SEQ ID NO: 503.

[0019] This document also provides a polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 502. In some embodiments, the sequence has at least about 90% or 95% identity with SEQ ID NO: 502. In some embodiments, the sequence comprises SEQ ID NO: 502.

[0020] This document also provides a polypeptide composition comprising: a targeting polypeptide containing a sequence having at least 80% identity with SEQ ID NO: 22 (LLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWT); and a therapeutic polypeptide containing bone morphogenetic protein (BMP). In some embodiments, the BMP is BMP-2.

[0021] This article also provides a nucleic acid encoding the polypeptide composition described herein. A vector comprising the nucleic acid is also provided.

[0022] This document also provides an apparatus comprising the polypeptide composition described herein and a carrier material. In some embodiments, the polypeptide composition is bound to the carrier material. In some embodiments, the carrier material comprises calcium phosphate. In some embodiments, the carrier material comprises hydroxyapatite. In some embodiments, the carrier material comprises tricalcium alpha phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) such as silicates, vanadates, and related ceramic minerals, or chelated divalent metal ions or any combination thereof.

[0023] This document also provides a method for treating a subject in need, the method comprising delivering to the subject the polypeptide composition or the device described herein. In some embodiments, the polypeptide composition or device is delivered to treat a bone defect in the subject. In some embodiments, at least about 0.5 mg of polypeptide composition / cc of defect volume is delivered to the subject. In some embodiments, about 0.5 mg to about 10 mg of polypeptide composition / cc of defect volume is delivered to the subject.

[0024] This document also provides a method for delivering a therapeutic agent to an organ or tissue of a subject, the method comprising delivering a carrier material and a therapeutic agent to the organ or tissue, wherein the therapeutic agent is bound to the carrier material via a targeting peptide comprising: (a) a sequence having at least 80% identity with SEQ ID NO: 22, (b) a sequence having at least 80% identity with SEQ ID NO: 402, (c) a sequence having at least 80% identity with SEQ ID NO: 401, (d) a sequence having at least 80% identity with SEQ ID NO: 413((X1)(X2)), wherein X1 comprises SEQ ID NO: 1, and X2 comprises SEQ ID NO: 2 and SEQ ID NO: 6, (e) a sequence having at least 80% identity with SEQ ID NO: 21, and (f) a sequence having at least 80% identity with SEQ ID NO: 414((X1)(X2)), wherein X1 comprises SEQ ID NO: 2, and X2 comprises SEQ ID NO: 6 and SEQ ID NO: 7. 7, (g) A sequence having at least 80% identity with SEQ ID NO: 416 ((X1)(X2)), wherein X1 contains SEQ ID NO: 6 and X2 contains SEQ ID NO: 7 and SEQ ID NO: 4; (h) A sequence having at least 80% identity with SEQ ID NO: 408 ((X1)(X2)), wherein X1 contains SEQ ID NO: 1 and X2 contains SEQ ID NO: 2; (i) A sequence having at least 80% identity with SEQ ID NO: 20; (j) A sequence having at least 80% identity with SEQ ID NO: 409 ((X1)(X2)), wherein X1 contains SEQ ID NO: 2 and X2 contains SEQ ID NO: 6; (k) A sequence having at least 80% identity with SEQ ID NO: 411 ((X1)(X2)), wherein X1 contains SEQ ID NO: 6 and X2 contains SEQ ID NO: 7; (l) A sequence having at least 80% identity with SEQ ID NO: 408 ((X1)(X2)), wherein X1 contains SEQ ID NO: 6 and X2 contains SEQ ID NO: 408 ((X1)(X2)), wherein X1 contains SEQ ID NO: 1 ... 412 ((X1)(X2)) sequences having at least 80% identity, wherein X1 contains SEQ ID NO: 7 and X2 contains SEQ ID NO: 4, (m) a sequence having at least 80% identity with SEQ ID NO: 2 (VIGESTHHRPWS), (n) a sequence having at least 80% identity with SEQ ID NO: 4 (ILAESTHHKPWT), and (o) a sequence having at least 80% identity with SEQ ID NO: 6 (IIGESSHHKPFT).(p) is a sequence having at least 80% identity with SEQ ID NO: 7 (GLGDTTHHRPWG), or (q) any combination of two or more of (a) to (p). In some embodiments, the carrier material comprises calcium phosphate. In some embodiments, the targeting peptide is linked to a therapeutic agent. In some embodiments, the therapeutic agent comprises a growth factor. In some embodiments, the therapeutic agent comprises BMP. In some embodiments, the BMP comprises BMP-2. In some embodiments, the therapeutic agent comprises a sequence having at least about 80% identity with SEQ ID NO: 32. In some embodiments, the therapeutic agent comprises a sequence having at least about 80% identity with any one of SEQ ID NO: 46-71, 73-77, 79-101, 152, 168, 176, 268. In some embodiments, the therapeutic agent is delivered to treat a bone defect in a subject. In some embodiments, at least about 0.5 mg of the therapeutic agent is delivered per cc of defect volume. In some embodiments, about 0.5 mg to about 10 mg of the therapeutic agent is delivered per cc of defect volume.

[0025] This article also provides chimeric peptides comprising: (i) targeting peptides comprising one or more of the following: amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VIGESTHHRPWS (SEQ ID NO: 2), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LIADSTHHSPWT (SEQ ID NO: 3) and ILAESTHHKPWT (SEQ ID NO: 4), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with ILAESTHHRPWS (SEQ ID NO: 5), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with IIGESSHHKPFT (SEQ ID NO: 6), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GLGDTTHHRPWG (SEQ ID NO: 4 ... 7) Amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VLGDTTHHKPWT (SEQ ID NO: 8), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with IVADSTHHRPWT (SEQ ID NO: 9), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with STADTSHHRPS (SEQ ID NO: 10), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TSGGESTHHRPS (SEQ ID NO: 11), amino acid sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TSGGESSHHK ... 12) An amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TGSGDSSHHRPS (SEQ ID NO: 13), an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GSSGESTHHKPST (SEQ ID NO: 14), and an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VGADSTHHRPVT (SEQ ID NO: 14).15) an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with GADTTHHRPVT (SEQ ID NO: 16), an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with GADTTHHRPVT (SEQ ID NO: 17), an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with GGADTTHHRPAT (SEQ ID NO: 18), and an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with GGADTTHHRPGT (SEQ ID NO: 19); and (ii) a mammalian growth factor.

[0026] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 2. In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 2. In some embodiments, the targeting peptide comprises SEQ ID NO: 2.

[0027] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 4. In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 4. In some embodiments, the targeting peptide comprises SEQ ID NO: 4.

[0028] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 6. In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 6. In some embodiments, the targeting peptide comprises SEQ ID NO: 6.

[0029] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 7. In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 7. In some embodiments, the targeting peptide comprises SEQ ID NO: 7.

[0030] In some embodiments, the targeting peptide comprises two or more targeting peptides. In some embodiments, the two or more targeting peptides are no more than about 50, 45, 40, 35, 30, 25, 20, 15, or 10 targeting peptides. In some embodiments, the two or more targeting peptides are about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 targeting peptides. In some embodiments, the two or more targeting peptides are about 2 to about 10 targeting peptides. In some embodiments, the two or more targeting peptides are about 5 targeting peptides.

[0031] In some embodiments, the two or more targeting peptides in each adjacent pair are directly adjacent to each other. In some embodiments, at least two of the two or more targeting peptides are directly adjacent to each other.

[0032] In some embodiments, the two or more target peptides in each adjacent pair are separated by an adapter sequence. In some embodiments, at least two of the two or more target peptides are separated by an adapter sequence.

[0033] In some implementations, the targeting peptide comprises at least two different peptides.

[0034] In some implementations, the targeting peptide comprises two or more copies of the same peptide.

[0035] In some embodiments, the targeting peptide further comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 1. In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 1. In some embodiments, the targeting peptide comprises SEQ ID NO: 1.

[0036] In some embodiments, the targeting peptide comprises: (i) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 1; (ii) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 2; (iii) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 4; (iv) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 6; (v) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 7; or (vi) any combination of (i) to (v). In some embodiments, the targeting peptide comprises (i), (ii), (iii), (iv), and (v). In some embodiments, the targeting peptide comprises SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7. In some embodiments, the targeting peptide comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7.

[0037] In some embodiments, the targeting peptide comprises LLADTTHHRPWT (SEQ ID NO: 1) and / or GQVLPTTTPSSP (SEQ ID NO: 44).

[0038] In some embodiments, the targeting peptide comprises LLADTTHHRPWT (SEQ ID NO: 1) and / or VIGESTHHRPWS (SEQ ID NO: 2).

[0039] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTVIGESTHHRPWS (SEQ ID NO: 20). In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 20. In some embodiments, the targeting peptide comprises SEQ ID NO: 20.

[0040] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWT (SEQ ID NO: 1), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VIGESTHHRPWS (SEQ ID NO: 2), and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with IIGESTHHRPWS (SEQ ID NO: 6). In some embodiments, the targeting peptide comprises a sequence having at least 90% identity with SEQ ID NO: 1, a sequence having at least 90% identity with SEQ ID NO: 2, and a sequence having at least 90% identity with SEQ ID NO: 6. In some embodiments, the targeting peptide comprises SEQ ID NO: 1, 2, and 6.

[0041] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VIGESTHHRPWS (SEQ ID NO: 2) and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with IIGESSHHKPFT (SEQ ID NO: 6). In some embodiments, the targeting peptide comprises a sequence having at least 90% identity with SEQ ID NO: 2 and a sequence having at least 90% identity with SEQ ID NO: 6. In some embodiments, the targeting peptide comprises SEQ ID NO: 2 and 6.

[0042] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFT (SEQ ID NO: 21). In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 21. In some embodiments, the targeting peptide comprises SEQ ID NO: 21.

[0043] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWG (SEQ ID NO: 401). In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 401. In some embodiments, the targeting peptide comprises SEQ ID NO: 401.

[0044] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWT (SEQ ID NO: 402). In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 402. In some embodiments, the targeting peptide comprises SEQ ID NO: 402.

[0045] In some embodiments, the targeting peptides comprise LLADTTHHRPWT (SEQ ID NO: 1), VIGESTHHRPWS (SEQ ID NO: 2), IIEGESSHHKPFT (SEQ ID NO: 6), GLGDTTHHRPWG (SEQ ID NO: 7), and ILAESTHHKPWT (SEQ ID NO: 4).

[0046] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWT (SEQ ID NO: 22). In some embodiments, the targeting peptide comprises a sequence having at least about 80% identity with SEQ ID NO: 22. In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 22. In some embodiments, the targeting peptide comprises SEQ ID NO: 22.

[0047] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWT (SEQ ID NO: 1) and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with ILAESTHHKPWT (SEQ ID NO: 4). In some embodiments, the targeting peptide comprises a sequence having at least 90% identity with SEQ ID NO: 1 and a sequence having at least 90% identity with SEQ ID NO: 4. In some embodiments, the targeting peptide comprises both SEQ ID NO: 1 and SEQ ID NO: 4.

[0048] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTILAESTHHKPWT (SEQ ID NO:23).

[0049] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTILAESTHHKPWTLLADTTHHRPWTILAESTHHKPWTLLADTTHHRPWT (SEQ ID NO: 24).

[0050] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWT (SEQ ID NO: 1) and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GLGDTTHHRPWG (SEQ ID NO: 7). In some embodiments, the targeting peptide comprises a sequence having at least about 90% identity with SEQ ID NO: 1 and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 7. In some embodiments, the targeting peptide comprises both SEQ ID NO: 1 and SEQ ID NO: 7.

[0051] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTGLGDTTHHRPWG (SEQ ID NO:25).

[0052] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTGLGDTTHHRPWGLLADTTHHRPWT (SEQ ID NO: 26).

[0053] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTGLGDTTHHRPWGLLADTTHHRPWTGLGDTTHHRPWGLLADTTHHRPWT (SEQ ID NO: 27).

[0054] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWTGLGDTTHHRPWGLLADTTHHRPWTGLGDTTHHRPWGLLADTTHHRPWTGLGDTTHHRPWGLLADTTHHRPWT (SEQ ID NO: 28).

[0055] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with STADTSHHRPS (SEQ ID NO: 10), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TSGGESTHHRPS (SEQ ID NO: 11), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TSGGESSHHKPS (SEQ ID NO: 12), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TGSGDSSHHRPS (SEQ ID NO: 13), and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GSSGESTHHKPST (SEQ ID NO: 14).

[0056] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with STADTHHRPSTSGGESTHHRPSTSGGESSHHKPSTGSGDSSHHRPSGSSGESTHHKPST (SEQ ID NO: 29).

[0057] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VGADSTHHRPVT (SEQ ID NO: 15), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GADTTHHRPVT (SEQ ID NO: 16), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with AGADTTHHRPVT (SEQ ID NO: 17), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GGADTTHHRPAT (SEQ ID NO: 18), and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GGADTTHHRPGT (SEQ ID NO: 19).

[0058] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with VGADSTHHRPVTGAADTTHHRPVTAGADTTHHRPVTGGADTTHHRPATGGADTTHHRPGT (SEQ ID NO: 30).

[0059] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with STADTSHHRPS (SEQ ID NO: 10), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with LLADTTHHRPWT (SEQ ID NO: 1), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TSGGESTHHRPS (SEQ ID NO: 11), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with VGADSTHHRPVT (SEQ ID NO: 15), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TSGGESSHHKPS (SEQ ID NO: 12), and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GADTTHHRPVT. (SEQ ID NO: 16) A sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with TGSGDSSHHRPS (SEQ ID NO: 13), a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with GSSGESTHHKPST (SEQ ID NO: 14), and a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with GGADTTHHRPAT (SEQ ID NO: 18).

[0060] In some embodiments, the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with STADTSHHRPSLLADTTHHRPWTTSGGESTHHRPSVGADSTHHRPVTTSGGESSHHKPSGAADTTHHRPVTTGSGDSSHHRPSGSSGESTHHKPSTGGADTTHHRPAT (SEQ ID NO: 31).

[0061] In some embodiments, the targeting peptide comprises the amino acid sequence of Formula I: A0B0C0D0E0F0G0H0I0J0K0L0 (Formula I) (SEQ ID NO: 35), wherein: A0 is V, L, I, G, S, T, or A; B0 is I, L, V, Q, T, S, G, or A; C0 is G, A, V, or S; D0 is E, D, L, or G; E0 is S, T, P, T, E, or D; F0 is T or S; G0 is H, T, or S; H0 is H or T; I0 is R, S, K, P, or H; J0 is P, S, R, or K; K0 is W, F, S, P, V, A, or G; and L0 is absent or is S, T, G (or A). In some embodiments, Formula I does not contain LLADTTHHRPWT (SEQ ID NO: 1).

[0062] In some embodiments, the targeting polypeptide comprises two or more amino acid sequences having Formula I. In some embodiments, at least two of the two or more amino acid sequences are different. In some embodiments, at least two of the two or more amino acid sequences are the same. In some embodiments, the two or more amino acid sequences are about 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0063] In some embodiments, at least two of the two or more amino acid sequences having Formula I are directly adjacent to each other. In some embodiments, each of the two or more amino acid sequences having Formula I is directly adjacent to each other.

[0064] In some embodiments, at least two of the two or more amino acid sequences of Formula I are separated by a linker sequence. In some embodiments, each of the two or more amino acid sequences of Formula I is separated by a linker sequence.

[0065] In some embodiments of any of the chimeric polypeptides described herein, the mammalian growth factor includes one or more of the following: epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-1), fibroblast growth factor (FGF), fibroblast growth factor 2 (FGF2), fibroblast growth factor 18 (FGF18), transforming growth factor α (TGF-α), transforming growth factor β (TGF-β), transforming growth factor β1 (TGF-β1), transforming growth factor β3 (TGF-β3), osteoblast protein 1 (OP-1), osteoblast protein 2 (OP-2), osteoblast protein 3 (OP-3), bone morphogenetic protein 2 (BMP-2), bone morphogenetic protein 3 (BMP-3), bone morphogenetic protein 4 (BMP-4), bone morphogenetic protein 5 (BMP-5), bone morphogenetic protein 6 (BMP-6), bone morphogenetic protein 7 (BMP-7), bone morphogenetic protein 9, and bone morphogenetic protein 10. Bone morphogenetic protein 10 (BMP-10), bone morphogenetic protein 11 (BMP-11), bone morphogenetic protein 12 (BMP-12), bone morphogenetic protein 13 (BMP-13), bone morphogenetic protein 15 (BMP-15), dentin phosphoprotein (DPP), and vegetable-related growth factor (VRF).Vgr), Growth Differentiation Factor 1 (GDF-1), Growth Differentiation Factor 3 (GDF-3), Growth Differentiation Factor 5 (GDF-5), Growth Differentiation Factor 6 (GDF-6), Growth Differentiation Factor 7 (GDF-7), Growth Differentiation Factor 8 (GDF8), Growth Differentiation Factor 11 (GDF11), Growth Differentiation Factor 15 (GDF15), Vascular Endothelial Growth Factor (VEGF), Hyaluronic Acid-Binding Protein (HABP), Collagen-Binding Protein (CBP), Fibroblast Growth Factor 18 (FGF-18), Keratinocyte Growth Factor (KGF), Tumor Necrosis Factor α (TNFα), Tumor Necrosis Factor (TNF)-Associated Apoptosis-Inducing Ligand (TRAIL), WNT Family Member 1 (WNT1), WNT Family Member 2 (WNT2), WNT Family Member 2B (WNT2B), WNT Family Member 3 (WNT3), WNT Family Member 3A (WNT3A), WNT Family Member 4 (WNT4), WNT Family Member 5A (WNT5A), WNT Family Member 5B WNT5B, WNT family member 6 (WNT6), WNT family member 7A (WNT7A), WNT family member 7B (WNT7B), WNT family member 8A (WNT8A), WNT family member 8B (WNT8B), WNT family member 9A (WNT9A), WNT family member 9B (WNT9B), WNT family member 10A (WNT10A), WNT family member 10B (WNT10B), WNT family member 11 (WNT11), neuroregulatory protein 1 (NRG1) or WNT family member 16 (WNT16).

[0066] In some embodiments of any of the chimeric polypeptides described herein, the mammalian growth factor includes one or more functional portions of the following: epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-1), fibroblast growth factor (FGF), fibroblast growth factor 2 (FGF2), fibroblast growth factor 18 (FGF18), transforming growth factor α (TGF-α), transforming growth factor β (TGF-β), transforming growth factor β1 (TGF-β1), transforming growth factor β3 (TGF-β3), osteoblast protein 1 (OP-1), osteoblast protein 2 (OP-2), osteoblast protein 3 (OP-3), bone morphogenetic protein 2 (BMP-2), bone morphogenetic protein 3 (BMP-3), bone morphogenetic protein 4 (BMP-4), bone morphogenetic protein 5 (BMP-5), bone morphogenetic protein 6 (BMP-6), bone morphogenetic protein 7 (BMP-7), bone morphogenetic protein 9 (BMP-9), and bone morphogenetic protein 10. Bone morphogenetic protein 10 (BMP-10), Bone morphogenetic protein 11 (BMP-11), Bone morphogenetic protein 12 (BMP-12), Bone morphogenetic protein 13 (BMP-13), Bone morphogenetic protein 15 (BMP-15), Dentin phosphoprotein (DPP), Plant-associated growth factor (Vgr), Growth differentiation factor 1 (GDF-1), Growth differentiation factor 3 (GDF-3), Growth differentiation factor 5 (GDF-5), Growth differentiation factor 6 (GDF-6), Growth differentiation factor 7 (GDF-7), Growth differentiation factor 8 (GDF8), Growth differentiation factor 11 (GDF11), Growth differentiation factor 15 (GDF15), Vascular endothelial growth factor (VEGF), Hyaluronic acid-binding protein (HABP), Collagen-binding protein (CBP), Fibroblast growth factor 18 (FGF-18), Keratinocyte growth factor (KGF), Tumor necrosis factor α (TNFα), Tumor necrosis factor (TNF)-associated apoptosis-inducing ligand (TRAIL), Wnt family member 1 (WNT1), WNT family member 2 (WNT2), WNT family member 2B (WNT2B), WNT family member 3 (WNT3), WNT family member 3A (WNT3A), WNT family member 4 (WNT4), WNT family member 5A (WNT5A), WNT family member 5B (WNT5B), WNT family member 6 (WNT6), WNT family member 7A (WNT7A), WNT family member 7B (WNT7B), WNT family member 8A (WNT8A), WNT family member 8B (WNT8B), WNT family member 9A (WNT9A), WNT family member 9B(WNT9B), WNT family member 10A (WNT10A), WNT family member 10B (WNT10B), WNT family member 11 (WNT11), neuroregulatory protein 1 (NRG1), or WNT family member 16 (WNT16).

[0067] In some embodiments, the mammalian growth factor comprises BMP-2. In some embodiments, the mammalian growth factor comprises a functional portion of BMP-2. In some embodiments, the mammalian growth factor comprises a mature BMP-2 peptide without a signal sequence. In some embodiments, the functional portion of BMP-2 comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR (SEQ ID NO: 32). In some embodiments, the mammalian growth factor comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with the sequence in Table B. In some embodiments, the mammalian growth factor comprises a sequence having at least about 90% identity with SEQ ID NO: 32. In some implementations, the mammalian growth factor contains SEQ ID NO: 32.

[0068] In some embodiments, the chimeric polypeptide comprises: (a) a targeting polypeptide comprising: (i) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 1; (ii) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 2; (iii) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 4; (iv) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 6; (v) a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 1; 7. A sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity; or (vi) any combination of (i) to (v); and (b) a mammalian growth factor comprising a functional portion of BMP-2. In some embodiments, the functional portion of BMP-2 comprises SEQ ID NO: 32. In some embodiments, the chimeric polypeptide comprises: a targeting polypeptide comprising SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7; and a mammalian growth factor comprising SEQ ID NO: 32. In some embodiments, the targeting polypeptide and the mammalian growth factor are linked by a linker polypeptide.

[0069] In some embodiments, the chimeric polypeptide comprises: a targeting polypeptide comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 402; and a mammalian growth factor comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some embodiments, the chimeric polypeptide comprises: a targeting polypeptide comprising a sequence having at least about 90% identity with SEQ ID NO: 402; and a mammalian growth factor comprising a sequence having at least about 90% identity with SEQ ID NO: 32. In some embodiments, the targeting polypeptide and the mammalian growth factor are linked by a linker polypeptide.

[0070] In some embodiments, the chimeric polypeptide comprises: a targeting polypeptide comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 22; and a mammalian growth factor comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some embodiments, the chimeric polypeptide comprises: a targeting polypeptide comprising a sequence having at least about 90% identity with SEQ ID NO: 22; and a mammalian growth factor comprising a sequence having at least about 90% identity with SEQ ID NO: 32. In some embodiments, the targeting polypeptide and the mammalian growth factor are linked by a linker polypeptide.

[0071] In some embodiments of any of the chimeric peptides described herein, the chimeric peptide further comprises a linker sequence. In some embodiments, the linker sequence connects the targeting peptide and a mammalian growth factor.

[0072] In some embodiments, the connector sequence comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with TGGSGEGGTGASTGGSAGTGGSGGTTSGEAGGSSGAG (SEQ ID NO: 33).

[0073] In some implementations, the connector sequence contains at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with GAGTG (SEQ ID NO: 34).

[0074] In some embodiments, the chimeric polypeptide includes a flexible linker comprising a sequence of about 5 to about 50 amino acids, wherein at least about five of the amino acids do not have a regular secondary structure. In some embodiments, the regular secondary structure includes any helical structure, such as an α-helix or a 3-helix. 10 The joint may contain helical or π-helical structures, β-turns, ω-loops, and / or β-folds. In some embodiments, the flexible joint comprises at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% glycine, alanine, serine, glycine and alanine, glycine and serine, alanine and serine, or glycine, alanine, and serine. In some embodiments, the joint comprises 1, 2, 3, 4, or 5 GSEGs (SEQ ID NO: 702). In some embodiments, the joint comprises 1, 2, 3, 4, or 5 SEGGs (SEQ ID NO: 703).

[0075] In some embodiments, the chimeric polypeptide comprises a linker sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with ASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTG (SEQ ID NO: 701). In some embodiments, the linker comprises a sequence having at least about 90% identity with SEQ ID NO: 701. In some embodiments, the linker comprises SEQ ID NO: 701.

[0076] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 90% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 91% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 92% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 93% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 94% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 95% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 96% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 97% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 98% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises a sequence having at least about 99% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 502.

[0077] In some embodiments of any of the chimeric peptides described herein, the chimeric peptide binds to a carrier material. In some embodiments, the targeting peptide binds to the carrier material. In some embodiments, the carrier material comprises calcium phosphate. In some embodiments, the carrier material comprises β-TCP. In some embodiments, the carrier material comprises hydroxyapatite. In some embodiments, the targeting peptide is expressed in K+ at a concentration of about 1 picomolar to about 100 micromolar. D Combined with carrier materials. In some embodiments, the targeting peptide is in the form of approximately 1 picomolar to approximately 100 micromolar K. D Combined with β-TCP. In some implementations, K is measured using methods known in the art and / or described herein. D .

[0078] This document also provides compositions comprising any of the chimeric peptides described herein.

[0079] In some embodiments, the composition comprises a carrier material. In some embodiments, the carrier material comprises calcium phosphate. In some embodiments, the carrier material comprises β-TCP. In some embodiments, the carrier material comprises hydroxyapatite. In some embodiments, the carrier material is formulated as a powder, putty, or paste. In some embodiments, the carrier material comprises a scaffold, fibers, mesh, or sponge.

[0080] In some embodiments of any of the compositions described herein, the composition is a pharmaceutical composition.

[0081] This document also provides kits that include any of the peptides, carrier materials, and / or compositions described herein.

[0082] This article also provides a target peptide for any of the chimeric peptides described herein.

[0083] This article also provides a method for promoting bone or cartilage formation in a subject in need, the method comprising: administering to the subject a therapeutically effective amount of any of the polypeptides and / or compositions described herein.

[0084] This article also provides a method for replacing and / or repairing bone or cartilage in a subject in need, the method comprising: administering a therapeutically effective amount of any of the polypeptides and / or compositions described herein to the subject.

[0085] This article also provides a method for treating fractures or bone loss in a subject in need, the method comprising: administering to the subject a therapeutically effective amount of any of the polypeptides and / or compositions described herein.

[0086] In some embodiments of the methods described herein, the subject suffers from a fracture. In some embodiments of the methods described herein, the subject suffers from a bone defect. In some embodiments of the methods described herein, the subject suffers from a cartilage tear or cartilage defect. In some embodiments of the methods described herein, the subject suffers from cartilage loss.

[0087] As used herein, the term "object" refers to any mammal. Therefore, an object means, for example, a mouse, rat, dog, cat, horse, cow, pig, guinea pig, human, monkey, etc. When the object is a human, the object may be referred to herein as a patient. In some embodiments, the object or "object requiring treatment" may be a canine (e.g., a dog), a feline (e.g., a cat), an equine (e.g., a horse), a sheep, a bovine, a suidae, a caprine, a primate such as an ape (e.g., a monkey (e.g., a marmoset, a baboon) or an ape (e.g., a gorilla, a chimpanzee, an orangutan, or a gibbon), a human, or a rodent (e.g., a mouse, a guinea pig, a hamster, or a rat). In some embodiments, the object or "object requiring treatment" may be a non-human mammal, particularly a mammal conventionally used as a model for demonstrating therapeutic efficacy in humans (e.g., a rodent, a rabbit, a suidae, a canine, or a primate).

[0088] In some implementations, the term "therapeuticly effective amount" refers to the amount of a polypeptide or composition that effectively "treats" a disease, symptom, or condition. In some cases, a therapeutically effective amount of a polypeptide or composition reduces the severity of symptoms of a disease, symptom, or condition. In some cases, a disease, symptom, or condition includes defects in an organ or tissue.

[0089] "Affinity" refers to the strength of the sum of non-covalent interactions between a β-TCP binding sequence (or a chimeric polypeptide or a polypeptide containing a β-TCP binding sequence) and its binding partner (e.g., β-TCP). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) techniques (e.g., BIACORE®) or biolayer interferometry (e.g., FORTEBIO®). Other methods for determining affinity are known in the art.

[0090] The percentage of sequence identity (%) of a reference polypeptide sequence is the percentage of amino acid residues in the candidate sequence that are identical to those in the reference polypeptide sequence after alignment and cleavage (if necessary) to achieve the maximum percentage of sequence identity, and without considering any conserved substitutions as part of the sequence identity. Alignments used to determine the percentage of amino acid sequence identity can be performed in a variety of known ways, such as using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Appropriate parameters for alignment can be determined, including the algorithms required to achieve maximum alignment across the full length of the compared sequences. However, for the purposes of this paper, the amino acid sequence identity % value is generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code has been submitted as a user document to the US Copyright Office at Washington DC, 20559, where it is registered under US Copyright Registry No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. in South San Francisco, California, or can be compiled from source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not change.

[0091] When ALIGN-2 is used for amino acid sequence comparison, the percentage of amino acid sequence identity of a given amino acid sequence A with respect to, and or relative to, a given amino acid sequence B (which can be alternatively phrased as a given amino acid sequence A having or containing a certain percentage of amino acid sequence identity with respect to, and or relative to, a given amino acid sequence B) is calculated as follows: 100 × fraction X / Y, where X is the number of amino acid residues that are scored as identical matches in the alignment of A and B by the sequence alignment program ALIGN-2, and where Y is the total number of amino acid residues in B. It should be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percentage of amino acid sequence identity between A and B will not be equal to the percentage of amino acid sequence identity between B and A. Unless otherwise explicitly stated, all amino acid sequence identity percentage values ​​used herein were obtained using the ALIGN-2 computer program as described immediately following the previous paragraph.

[0092] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Methods and materials are described herein for their use in this invention; other suitable methods and materials known in the art may also be used. Materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database items, and other references mentioned herein are incorporated herein by reference in their entirety. In case of any conflict, this specification and its included definitions shall prevail.

[0093] Other features and advantages of the invention will be apparent from the following detailed description and drawings, as well as from the claims. Attached Figure Description

[0094] Figure 1A These are representative in vivo X-ray images (lateromedial orientation) of animals from experimental group A.

[0095] Figure 1B These are representative in vivo X-ray images (external-internal orientation) of animals from experimental group B.

[0096] Figure 1C These are representative in vivo X-ray images (external-internal orientation) of animals from experimental group C.

[0097] Figure 2 This is a representative plot of the mean radiographic score (+SEM, n=9–10) of animals from each group at four and eight weeks post-surgery (for each group AC, the left bar is at 4 weeks and the right bar is at 8 weeks). *P<0.01 relative to group C1; #P<0.01 relative to group V; ┼P<0.01 relative to group C at 4 weeks.

[0098] Figure 3A These are representative radiographs, sagittal and transverse micro-CT images of animals from groups A, B, or C at 4 weeks post-surgery.

[0099] Figure 3B These are representative radiographs, sagittal and transverse micro-CT images of animals from groups A, B, or C at 4 weeks post-surgery.

[0100] Figure 4 This is a schematic diagram showing the different callus formation in animals of groups A, B, or C at 4 weeks post-surgery. The red shaded areas represent approximate volumes of mineralized callus.

[0101] Figure 5AThis is a representative image from the micro-CT analysis, showing the total callus volume in bone specimens obtained from animals in group A (n=9), group B (n=7), or group C (n=8) at 8 weeks post-surgery. Data are presented as mean ± SEM; *P < 0.01 relative to B, #P < 0.01 relative to C.

[0102] Figure 5B This is a representative image from a micro-CT analysis, showing bone mineral volume in bone specimens obtained from animals in group A (n=9), group B (n=7), or group C (n=8) at 8 weeks post-surgery. Data are presented as mean ± SEM; *P < 0.01 relative to B, #P < 0.01 relative to C.

[0103] Figure 6A This is a representative image of the diaphysis volume of bone specimens obtained 4 weeks post-surgery from animals in groups A (n=10), B (n=8), or C (n=7). Bone mineral volume is expressed as the percentage of bone mineral volume to total volume. Data are presented as mean ± SEM; *P < 0.05 relative to B, #P < 0.05 relative to C. A1 relative to B1; p = 0.059.

[0104] Figure 6B This is a representative image of cortical bone volume from bone specimens obtained 4 weeks post-surgery from animals in groups A (n=10), B (n=8), or C (n=7). Bone mineral volume is expressed as the percentage of bone mineral volume to total volume. Data are presented as mean ± SEM; *P < 0.05 relative to B, #P < 0.05 relative to C.

[0105] Figure 7A This is a representative image of the total callus volume in bone specimens obtained from animals in group A (n=9), group B (n=7), or group C (n=8) at 8 weeks post-surgery, based on micro-CT analysis. Data are presented as mean ± SEM; *P < 0.01 relative to B, #P < 0.01 relative to C.

[0106] Figure 7B This is a representative image of micro-CT analysis of bone mineral volume in bone specimens obtained from animals in group A (n=9), group B (n=7), or group C (n=8) at 8 weeks post-surgery. Data are presented as mean ± SEM; *P < 0.01 relative to B, #P < 0.01 relative to C.

[0107] Figure 8This is a representative plot of ultimate failure load (ULF) at 4 and 8 weeks post-surgery for animals in groups A, B, or C (for each in groups A and C, the left bar represents 4 weeks and the right bar represents 8 weeks). Data are presented as mean + / - SEM. *P < 0.05 relative to the 4-week group; #P < 0.01 relative to the 8-week group.

[0108] Figure 9A These are representative histological images of Von Kossa and H&E stained bone specimens obtained from animals in groups A, B, or C at 4 weeks post-surgery.

[0109] Figure 9B These are representative histological images of TRAP+ osteoclast-stained bone specimens obtained 4 weeks post-surgery from animals in groups A, B, or C (left, middle, and right images, respectively). White arrows indicate osteoclasts, and yellow arrows indicate osteocytes.

[0110] Figure 10A These are representative Von Kossa and H&E stained histological images of bone specimens obtained from animals in groups A, B, or C at 8 weeks post-surgery.

[0111] Figure 10B These are representative TRAP+ osteoclast-stained histological images of bone specimens obtained 8 weeks post-surgery from animals in groups A, B, or C (left, middle, and right images, respectively). White arrows indicate osteoclasts, and yellow arrows indicate osteocytes.

[0112] Figure 11 This is a representative immunoblot of MCF-7 cell lysates detected with anti-P-Akt antibody, in which MCF-7 cells were incubated with β-TCBP-HRG.

[0113] Figure 12 This is a representative immunoblot of MCF-7 lysates detected by anti-P-Akt antibody, in which MCF-7 cells were incubated with either β-TCBP-HRG (free) or β-TCBP-HRG (β-TCP bound).

[0114] Figure 13 The procedure for inducing tibial defects in goats, as described in Example 6, is described in general.

[0115] Figure 14A These are mean radial BV and mean moment angle plots, which illustrate the pattern and extent of new bone mineralization in the defect sites of each treatment group.

[0116] Figure 14BThis is a total bone volume map of the 2.5 cm central region and the 5 cm total defect region. Changes in total new bone volume were measured in the treated goats. At medium and high doses, tBMP-2 showed comparable bone formation, which was superior to the low-dose group and the matrix-only group. For each in the AD group, the left bar corresponds to the 2.5 cm central region, and the right bar corresponds to the 5 cm region.

[0117] Figure 14C This is the dose-response model fitting curve built using nonlinear least squares regression based on bone volume data from a 2.5 cm central region (red dot). The solid blue center line represents the fit of the dose-response model. The three orange dots from bottom to top indicate the model-estimated doses at 50%, 75%, and 90% of the maximum effect on a logarithmic scale. The orange line is the 75% confidence interval for such doses. Dose-response analysis showed that the dose of tBMP-2 had a statistically significant effect on the total bone volume generated in the 2.5 cm central region (p=0.0003). The modeling curves show that the initial response increases rapidly with doses ranging from "no dose" to "low dose" (=2.14 mg / cc), then becomes slower upon reaching a plateau. Above the 2.14 mg / cc dose, the additional benefit of increasing the tBMP-2 dose to obtain a higher bone volume appears negligible (the dose-response curve becomes a plateau line). A dose of 2 mg / cc of defect volume is sufficient to achieve a complete response.

[0118] Figure 14D This is a ranking of cadaveric radiographs (AP and ML views) of 22 tibial defects. Higher ranking numbers indicate more bone formation in the tibial defect (1 = complete bone healing to 22 = non-healing). Results in the control and low-dose groups showed almost no new bone growth at the defect site. Robust bone formation with some bone bridging was seen in the high- and medium-dose tBMP-2 groups (9 out of 15 goats). The high and medium-dose groups resulted in significantly larger new bone formation at the defect site compared to the other groups (“A” and “B”).

[0119] Figure 15 The procedure for inducing and treating tibial defects in sheep, as described in Example 7, is outlined in general.

[0120] Figure 16A These are representative radiographs from each month of the study described in Example 7, with the treatment group receiving 2 mgtBMP-2 / cc of defect volume.

[0121] Figure 16BThis is a graph of bone volume measured from CT images as described in Example 7. For each week of treatment, the bars from left to right (dark to light shades) represent: 2 mg / cc tBMP2, 5 mg / cc tBMP2, and autologous transplantation control.

[0122] Figure 16C These are representative radiographs (AP and ML views) of tibial defects under all conditions. Results in the 2 mg / cc dose group showed significant bone growth, consistent with the 5 mg / cc and control conditions. Results in multiple sheep tested were generally consistent.

[0123] Figure 16D This is a representative H&E histological image from the 2 mg / cc group at 8 weeks, showing normal bone formation at the cut end adjacent to the primitive cortex. Arrows indicate cortex (blue, upper right arrow), connective tissue (black, lower right arrow), cartilage tissue (grey, lower left arrow), and new bone growth (green, upper left arrow).

[0124] Figure 16E These are histological images of tetrachromium from the 2 mg / cc group. At 8 weeks, residual polymer fibers are visible. Some are surrounded by newly grown bone, and some are surrounded by connective tissue with multinucleated giant cells associated with the biodegradation of fibers. Detailed Implementation

[0125] This document provides peptides for targeted delivery of therapeutic agents to a subject, including a defective region. In some embodiments, the region includes bone, and the therapeutic agent is delivered to treat the bone defect. In some embodiments, the peptide is a targeting peptide comprising one or more peptides from Table A.

[0126] In some embodiments, the targeting peptide comprises formula I: A0B0C0D0E0F0G0H0I0J0K0L0 (Formula I) (SEQ ID NO: 35), wherein: A0 is V, L, I, G, S, T, or A; B0 is I, L, V, Q, T, S, G, or A; C0 is G, A, V, or S; D0 is E, D, L, or G; E0 is S, T, P, T, E, or D; F0 is T or S; G0 is H, T, or S; H0 is H or T; I0 is R, S, K, P, or H; J0 is P, S, R, or K; K0 is W, F, S, P, V, A, or G; and L0 is absent or is S, T, G (or A). In some embodiments, formula I does not include LLADTTHHRPWT (SEQ ID NO: 1).

[0127] This document also provides chimeric peptides comprising a targeting peptide and a therapeutic agent. In some embodiments, the therapeutic agent comprises one or more peptides from Table B. In some embodiments, any of the targeting and / or chimeric peptides described herein may be combined with one or more substrates comprising β-TCP (e.g., Mastergraft strip, Vitoss Foam Pack, chronOS Strip, Vitoss Micromorsels, LifeInk500, Hyperelastic Bone, bioactive glass, β-TCP powder, β-TCP spray-dried powder, hydroxyapatite powder, hydroxyapatite-coated bone screws, β-TCP particles, hydroxyapatite particles, and ReBOSSIS). In some embodiments, any of the targeting and / or chimeric peptides described herein may be combined with silicon nitride or a silicon nitride-containing substrate.

[0128] This document also provides compositions comprising any of the targeted and / or chimeric peptides described herein. In some embodiments, the compositions further comprise a substrate containing β TCP (e.g., Mastergraft strip, Vitoss FoamPack, chronOS Strip, Vitoss Micromorsels, LifeInk500, Hyperelastic Bone, bioactive glass, β TCP powder, β TCP spray-dried powder, hydroxyapatite powder, hydroxyapatite-coated bone screws, β TCP particles, hydroxyapatite particles, and ReBOSSIS). In some embodiments, the compositions further comprise a substrate containing silicon nitride.

[0129] This document also provides kits comprising any of these compositions. Methods for promoting bone or cartilage formation in a subject in need; methods for replacing and / or repairing bone or cartilage in a subject in need; and methods for treating fractures or bone loss in a subject in need, said methods comprising administering any of the compositions described herein to the subject.

[0130] Non-limiting aspects of these peptides, compositions, kits, and methods are described below and can be used without limitation in any combination. Other aspects of these peptides, compositions, kits, and methods are known in the art.

[0131] Chimeric Peptides In one aspect, this document provides a chimeric polypeptide comprising a targeting polypeptide (e.g., a polypeptide capable of binding to a carrier material) and a therapeutic agent. As used herein, the term "chimeric polypeptide" is interchangeable with "fusion protein," "polypeptide composition," etc. In some instances, the therapeutic agent comprises one or more peptides of Table B or a functional portion thereof. In some instances, the chimeric polypeptide comprises a targeting polypeptide containing a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 1-43 or 401-422. In some embodiments, the targeting polypeptide comprises Formula I. In some embodiments, the targeting polypeptide comprises two or more targeting polypeptides. In some embodiments, the two or more targeting polypeptides are no more than about 50, 45, 40, 35, 30, 25, 20, 15, or 10 targeting polypeptides. In some embodiments, the two or more targeting peptides are about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 targeting peptides. In some embodiments, the two or more targeting peptides are about 2 to about 10 targeting peptides. In some embodiments, the two or more targeting peptides are about 5 targeting peptides.

[0132] In some instances, the target peptide of the chimeric polypeptide comprises formula I: A0B0C0D0E0F0G0H0I0J0K0L0 (Formula I) (SEQ ID NO: 35), wherein: A0 is V, L, I, G, S, T or A; B0 is I, L, V, Q, T, S, G or A; C0 is G, A, V or S; D0 is E, D, L or G; E0 is S, T, P, T, E or D; F0 is T or S; G0 is H, T or S; H0 is H or T; I0 is R, S, K, P or H; J0 is P, S, R or K; K0 is W, F, S, P, V, A or G; and L0 is absent or is S, T, G or A.

[0133] Non-limiting examples of targeting peptides that may be present in any of the chimeric peptides described herein are listed in Table A below.

[0134] Table A. Exemplary Targeted Peptide Sequences Table C. Exemplary chimeric peptides

[0135] In some embodiments, any of the chimeric peptides described herein comprises one or more targeting peptides. In some embodiments, the chimeric peptide comprises one to ten targeting peptides. For example, the chimeric peptide comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 targeting peptides. In some embodiments, the targeting peptide comprises one or more peptides that bind to a carrier material. In some embodiments, the one or more peptides are about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 peptides. In some embodiments, the targeting peptide comprises about 10 to about 100, about 10 to about 90, about 10 to about 80, about 10 to about 70, about 10 to about 60, about 10 to about 50, about 10 to about 40, about 10 to about 30, about 20 to about 100, about 20 to about 90, about 20 to about 80, about 20 to about 70, about 20 to about 60, about 20 to about 50, about 20 to about 40, or about 30 to about 80 amino acids.

[0136] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 1. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0137] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 2. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0138] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 3. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0139] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 4. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0140] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 5. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0141] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 6. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0142] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 7. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0143] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 8. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0144] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 9. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0145] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 10. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0146] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 11. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0147] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 12. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0148] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 13. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0149] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 14. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0150] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 15. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0151] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 16. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0152] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 17. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0153] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 18. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0154] In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) sequence identity with SEQ ID NO: 19. In some embodiments, the chimeric polypeptide comprises one or more therapeutic agents of Table B, or a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with a therapeutic agent of Table B. As a non-limiting example, a therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods for treating organ and / or tissue defects are also provided, comprising administering chimeric peptides and / or compositions to a subject in need.

[0155] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 501. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 501. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0156] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 502. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 502. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0157] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 503. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 503. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0158] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 504. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 504. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0159] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 505. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 505. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0160] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 506. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 506. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0161] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 507. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 507. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0162] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 508, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 508. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0163] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 509, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 509. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0164] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 510, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 510. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0165] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 511, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 511. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0166] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 512, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 512. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0167] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 513, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 513. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0168] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 514, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 514. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0169] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 515, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 515. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0170] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 516, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 516. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0171] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 517, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 517. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0172] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 518, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 518. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0173] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 519, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 519. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0174] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 520, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 520. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0175] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 521, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 521. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0176] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 522, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 522. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0177] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 523, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 523. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0178] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 524, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 524. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0179] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 525, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 525. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0180] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 526, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 526. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0181] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 527, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 527. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0182] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 528, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 528. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0183] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 529, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 529. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0184] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 530, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 530. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0185] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 531, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 531. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0186] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 532, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 532. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0187] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 533, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 533. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0188] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 534, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 534. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0189] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 535, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 535. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0190] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 536, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 536. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0191] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 537, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 537. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0192] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 538, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 538. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0193] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 539, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 539. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0194] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 540, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 540. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0195] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 541, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 541. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0196] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 542, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 542. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0197] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 543, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 543. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0198] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 544, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 544. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0199] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 545, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 545. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0200] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 546, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 546. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0201] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 547, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 547. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0202] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 548, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 548. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0203] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 549, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 549. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0204] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 550, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 550. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0205] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 551, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 551. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0206] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 552, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 552. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0207] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 553, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 553. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0208] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 554, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 554. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0209] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 555, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 555. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0210] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 556, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 556. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0211] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 557, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 557. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0212] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 558, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 558. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0213] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 559, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 559. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0214] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 560, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 560. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0215] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 561, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 561. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0216] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 562, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 562. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0217] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 563, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 563. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0218] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 564, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 564. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0219] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 565, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 565. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0220] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 566, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 566. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0221] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 567, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 567. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0222] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 568, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 568. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0223] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 569, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 569. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0224] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 570, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 570. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0225] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 571, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 571. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0226] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 572, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 572. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0227] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 573, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 573. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0228] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 574, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 574. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0229] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 575, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 575. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0230] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 576, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 576. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0231] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 577, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 577. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0232] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 578, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 578. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0233] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 579, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 579. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0234] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 580, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 580. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0235] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 581, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 581. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0236] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 582, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 582. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0237] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 583, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 583. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0238] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 584, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 584. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0239] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 585, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 585. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0240] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 586, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 586. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0241] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 587, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 587. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0242] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 588, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 588. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0243] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 589, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 589. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0244] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 590, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 590. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0245] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 591, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 591. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0246] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 592, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 592. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0247] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 593, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 593. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0248] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 594, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 594. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0249] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 595, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 595. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0250] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 596, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 596. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0251] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 597, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 597. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0252] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 598, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 598. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0253] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 599, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 599. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0254] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 600, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 600. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0255] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 601, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 601. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0256] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 602, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 602. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0257] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 603, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 603. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0258] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 604, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 604. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0259] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 605, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 605. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0260] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 606, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 606. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0261] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 607, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 607. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0262] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 608, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 608. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0263] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 609, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 609. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0264] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 610, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 610. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0265] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 611, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 611. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0266] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 612, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 612. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0267] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 613, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 613. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0268] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 614, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 614. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0269] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 615, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 615. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0270] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 616, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 616. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0271] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 617, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 617. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0272] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 618, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 618. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0273] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 619, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 619. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0274] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 620, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 620. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0275] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 621, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 621. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0276] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 622, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 622. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0277] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 623, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 623. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0278] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 624, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 624. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0279] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 625, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 625. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0280] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 626, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 626. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0281] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 627, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 627. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0282] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 628, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 628. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0283] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 629, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 629. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0284] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 630, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 630. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0285] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 631, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 631. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0286] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 632, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 632. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0287] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 633, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 633. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0288] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 634, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 634. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0289] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 635, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 635. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0290] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 636, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 636. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0291] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 637, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 637. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0292] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 638, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 638. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0293] In some embodiments, the chimeric polypeptide comprises a sequence having at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 639, wherein the chimeric polypeptide comprises X. In some embodiments, the chimeric polypeptide comprises SEQ ID NO: 639. In some aspects, compositions comprising a chimeric polypeptide and a carrier material (e.g., the carrier material provided herein) are also provided. Non-limiting exemplary carrier materials may comprise one or more of the following: tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) (such as silicates, vanadates, and related ceramic minerals), and chelated divalent metal ions. In some aspects, methods of treating organ and / or tissue defects are also provided, comprising administering the chimeric polypeptide and / or composition to a subject in need.

[0294] In some embodiments, the chimeric peptide further includes a linker sequence between the two targeting peptides. In some embodiments, the chimeric peptide further includes a linker sequence between the targeting peptide and the therapeutic agent.

[0295] In some embodiments, the chimeric polypeptide includes a signal sequence at its N-terminus. In some embodiments, the chimeric polypeptide includes a tag sequence (e.g., a poly-His tag, chitin-binding protein (CBP), maltose-binding protein (MBP), strep tag, glutathione S-transferase (GST), thioredoxin, or an Fc region). Additional examples of tags are known in the art.

[0296] In some embodiments, the chimeric polypeptide includes a leader sequence at its N-terminus that assists polypeptide expression. As a non-limiting example, the leader sequence includes MPIGS (SEQ ID NO: 704).

[0297] This document provides non-limiting exemplary embodiments of chimeric peptides: (1) In a first embodiment, the chimeric peptide comprises a targeting peptide. (2) The chimeric peptide of embodiment 1, wherein the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 1. (3) The chimeric peptide of embodiment 1, wherein the targeting peptide comprises SEQ ID NO: 1. (4) The chimeric peptide of any of the preceding embodiments, wherein the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 2. (5) The chimeric peptide of any of the preceding embodiments, wherein the targeting peptide comprises SEQ ID NO: 2. (6) The chimeric peptide of any of the preceding embodiments, wherein the targeting peptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 3. (7) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 3. (8) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 4. (9) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 4. (10) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 5. (11) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 5. (12) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 6. (13) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 6. (14) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 7. (15) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 7.(16) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 8. (17) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 8. (18) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 9. (19) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 9. (20) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 10. (21) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 10. (22) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 11. (23) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 11. (24) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 12. (25) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 12. (26) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 13. (27) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 13. (28) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with SEQ ID NO: 14. (29) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 14.(30) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 15. (31) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 15. (32) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 16. (33) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 16. (34) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 17. (35) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 17. (36) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 18. (37) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 18. (38) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 19. (39) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 19. (40) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 20. (41) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 20. (42) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with SEQ ID NO: 21. (43) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 21.(44) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 22. (45) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 22. (46) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 23. (47) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 23. (48) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 24. (49) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 24. (50) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 25. (51) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 25. (52) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 26. (53) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 26. (54) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 27. (55) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 27. (56) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with SEQ ID NO: 28. (57) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 28.(58) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 29. (59) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 29. (60) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 30. (61) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 30. (62) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 31. (63) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 31. (64) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. (65) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 32. (66) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 33. (67) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 33. (68) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 34. (69) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 34. (70) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with SEQ ID NO: 35. (71) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 35.(72) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 36. (73) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 36. (74) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 37. (75) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 37. (76) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 38. (77) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 38. (78) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 39. (79) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 39. (80) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 40. (81) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 40. (82) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 41. (83) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 41. (84) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 42. (85) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 42.(86) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 43. (87) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 43. (88) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 401. (89) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 401. (90) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 402. (91) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 402. (92) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 403. (93) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 403. (94) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 404. (95) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 404. (96) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 405. (97) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 405. (98) The chimeric polypeptide according to any one of the foregoing embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 406. (99) The chimeric polypeptide according to any one of the foregoing embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 406.(100) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 407. (101) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 407. (102) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 408. (103) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 408. (104) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 409. (105) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 409. (106) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 410. (107) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 410. (108) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 411. (109) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 411. (110) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 412. (111) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 412. (112) The chimeric polypeptide according to any one of the foregoing embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with SEQ ID NO: 413. (113) The chimeric polypeptide according to any one of the foregoing embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 413.(114) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 414. (115) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 414. (116) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 415. (117) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 415. (118) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 416. (119) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 416. (120) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 417. (121) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 417. (122) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 418. (123) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 418. (124) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 419. (125) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 419. (126) The chimeric polypeptide according to any one of the foregoing embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity with SEQ ID NO: 420. (127) The chimeric polypeptide according to any one of the foregoing embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 420.(128) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 421. (129) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 421. (130) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 422. (131) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises SEQ ID NO: 422. (132) The chimeric polypeptide according to any one of the preceding embodiments, wherein the targeting polypeptide comprises Formula I. (133) The chimeric polypeptide according to any one of the preceding embodiments, comprising a therapeutic agent. (134) The chimeric polypeptide according to embodiment 133, wherein the therapeutic agent comprises a mammalian growth factor. (135) The chimeric polypeptide according to embodiment 133 or embodiment 134, wherein the therapeutic agent comprises bone morphogenetic protein (BMP). (136) The chimeric polypeptide according to embodiment 135, wherein the BMP comprises BMP-2. (137) The chimeric polypeptide according to embodiment 135, wherein the BMP comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO: 32. (138) The chimeric polypeptide according to embodiment 135, wherein the BMP peptide comprises SEQ ID NO: 32. (139) The chimeric polypeptide according to embodiment 133 or embodiment 134, wherein the therapeutic agent comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with the sequence shown in Table B. (140) The chimeric polypeptide according to embodiment 133 or 134, wherein the therapeutic agent comprises two or more therapeutic sequences, each therapeutic sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity with the sequences shown in Table B. (141) The chimeric polypeptide according to embodiment 140, wherein the two or more are 2, 3, 4, or 5 therapeutic sequences. (142) The chimeric polypeptide according to embodiment 140, wherein the two or more are two to about ten. (143) The chimeric polypeptide according to any one of the preceding embodiments, comprising a linker. (144) The chimeric polypeptide according to embodiment 143, wherein the linker comprises GSEG (SEQ ID NO: 702).(145) The chimeric polypeptide according to embodiment 143 or 144, wherein the linker comprises SEGG (SEQ ID NO: 703). (146) The chimeric polypeptide according to any one of embodiments 143-145, wherein the linker comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 701, or wherein the linker comprises SEQ ID NO: 701. (147) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 501, or wherein the chimeric polypeptide comprises SEQ ID NO: 501. (148) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 502, or wherein the chimeric polypeptide comprises SEQ ID NO: 502. (149) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 503, or wherein the chimeric polypeptide comprises SEQ ID NO: 503. (150) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 504, or wherein the chimeric polypeptide comprises SEQ ID NO: 504. (151) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 505, or said chimeric polypeptide comprises SEQ ID NO: 505. (152) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 506, or said chimeric polypeptide comprises SEQ ID NO: 506.(153) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 507, or wherein the chimeric polypeptide comprises SEQ ID NO: 507. (154) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 508, and said sequence comprising X; or wherein the chimeric polypeptide comprises SEQ ID NO: 508. (155) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 509, and said sequence comprising X; or wherein the chimeric polypeptide comprises SEQ ID NO: 509. (156) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 510, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 510. (157) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 511, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 511. (158) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 512, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 512. (159) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 513, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 513.(160) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 514, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 514. (161) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 515, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 515. (162) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 516, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 516. (163) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 517, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 517. (164) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 518, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 518. (165) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 519, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 519. (166) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 520, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 520.(167) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 521, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 521. (168) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 522, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 522. (169) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 523, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 523. (170) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 524, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 524. (171) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 525, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 525. (172) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 526, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 526. (173) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 527, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 527.(174) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 528, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 528. (175) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 529, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 529. (176) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 530, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 530. (177) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 531, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 531. (178) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 532, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 532. (179) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 533, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 533. (180) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 534, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 534.(181) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 535, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 535. (182) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 536, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 536. (183) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 537, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 537. (184) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 538, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 538. (185) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 539, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 539. (186) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 540, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 540. (187) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 541, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 541.(188) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 542, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 542. (189) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 543, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 543. (190) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 544, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 544. (191) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 545, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 545. (192) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 546, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 546. (193) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 547, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 547. (194) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 548, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 548.(195) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 549, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 549. (196) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 550, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 550. (197) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 551, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 551. (198) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 552, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 552. (199) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 553, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 553. (200) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 554, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 554. (201) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 555, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 555.(202) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 556, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 556. (203) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 557, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 557. (204) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 558, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 558. (205) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 559, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 559. (206) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 560, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 560. (207) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 561, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 561. (208) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 562, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 562.(209) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 563, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 563. (210) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 564, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 564. (211) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 565, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 565. (212) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 566, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 566. (213) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 567, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 567. (214) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 568, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 568. (215) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 569, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 569.(216) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 570, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 570. (217) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 571, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 571. (218) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 572, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 572. (219) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 573, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 573. (220) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 574, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 574. (221) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 575, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 575. (222) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 576, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 577.(223) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 578, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 579. (224) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 580, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 580. (225) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 581, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 581. (226) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 582, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 582. (227) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 583, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 583. (228) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 584, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 584. (229) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 585, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 585.(230) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 586, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 586. (231) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 587, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 587. (232) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 588, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 588. (233) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 589, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 589. (234) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 590, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 590. (235) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 591, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 591. (236) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 592, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 592.(237) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 593, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 593. (238) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 594, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 594. (239) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 595, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 595. (240) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 596, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 596. (241) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 597, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 597. (242) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 598, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 598. (243) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 599, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 599.(244) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 600, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 600. (245) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 601, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 601. (246) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 602, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 602. (247) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 603, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 603. (248) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 604, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 604. (249) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 605, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 605. (250) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 606, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 606.(251) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 607, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 607. (252) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 608, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 608. (253) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 609, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 609. (254) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 610, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 610. (255) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 611, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 611. (256) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 612, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 612. (257) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 613, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 613.(258) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 614, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 614. (259) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 615, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 615. (260) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 616, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 616. (261) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 617, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 617. (262) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 618, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 618. (263) The chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 619, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 619. (264) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 620, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 620.(265) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 621, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 621. (266) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 622, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 622. (267) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 623, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 623. (268) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 624, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 624. (269) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 625, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 625. (270) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 626, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 626. (271) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 627, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 627.(272) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 628, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 628. (273) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 629, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 629. (274) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 630, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 630. (275) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 631, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 631. (276) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 632, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 632. (277) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 633, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 633. (278) The chimeric polypeptide according to any one of the foregoing embodiments comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 634, and said sequence comprises X; or said chimeric polypeptide comprises SEQ ID NO: 634.(279) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 635, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 635. (280) The chimeric polypeptide according to any one of the foregoing embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 636, and said sequence comprising X; or said chimeric polypeptide comprising SEQ ID NO: 636. (281) A chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 637, and said sequence comprising X; or said chimeric polypeptide comprises SEQ ID NO: 637. (282) A chimeric polypeptide according to any one of the preceding embodiments, comprising a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 638, and said sequence comprising X; or said chimeric polypeptide comprises SEQ ID NO: 638. (283) A composition comprising a chimeric polypeptide according to any one of the preceding embodiments. (284) A composition according to embodiment 283, further comprising a carrier material. (285) A composition according to embodiment 284, wherein said targeting polypeptide binds to said carrier material. (286) The composition according to embodiment 284 or embodiment 285, wherein the carrier material comprises calcium phosphate. (287) The composition according to embodiment 286, wherein the calcium phosphate comprises tricalcium phosphate. (288) The composition according to embodiment 287, wherein the tricalcium phosphate comprises β-tricalcium phosphate. (289) The composition according to any one of embodiments 284-288, wherein the carrier material comprises hydroxyapatite. (290) The composition according to any one of embodiments 284-289, wherein the carrier material comprises α-tricalcium phosphate, fluorapatite, bone (e.g., demineralized bone), glass (bioglass) such as silicates, vanadates and related ceramic minerals, or chelated divalent metal ions or any combination thereof. (291) The composition according to any one of embodiments 284-290, wherein the carrier material comprises fibers, powders, putty, paste, mesh, sponge or scaffold or combinations thereof.(292) A method of treating a subject in need, the method comprising delivering to the subject a chimeric polypeptide according to any one of embodiments 1-282. (293) A method of treating a subject in need, the method comprising delivering to the subject a composition according to any one of embodiments 283-291. (294) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat bone defects of the subject. (295) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat cartilage defects of the subject. (296) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat soft tissue defects of the subject. (297) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat tendon defects of the subject. (298) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat fascia defects of the subject. (299) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat ligament defects of the subject. (300) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat organ defects of the subject. (301) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat osteotendinous tissue defects of the subject. (302) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat epidermal defects of the subject. (303) The method according to embodiment 292 or embodiment 293, wherein the chimeric polypeptide is used to treat osteochondral defects of the subject. (304) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve spinal fusion of the subject. (305) The method according to embodiment 304, wherein the spinal fusion includes posterior lumbar fusion (PLF). (306) The method according to embodiment 304, wherein the spinal fusion includes intervertebral fusion. (307) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve bone trauma repair. (308) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve tooth restoration. (309) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve craniomaxillofacial restoration. (310) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve ankle fusion. (311) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve vertebroplasty.(312) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve balloon osteotomy. (313) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve scaphoid fracture repair. (314) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve tendon bone repair. (315) The method according to embodiment 292 or embodiment 293, wherein the method is performed to treat osteoporosis. (316) The method according to embodiment 292 or embodiment 293, wherein the method is performed to treat avascular necrosis. (317) The method according to embodiment 292 or embodiment 293, wherein the method is performed to treat congenital skeletal deformities. (318) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve rib reconstruction. (319) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve subchondral bone repair. (320) The method according to embodiment 292 or embodiment 293, wherein the method is performed to achieve cartilage repair. (321) The method according to embodiment 292 or embodiment 293, wherein the method is performed on hair follicles (BMP-2 is involved in hair follicle development). (322) The method according to any one of embodiments 292-321, wherein the object is a mammal. (323) The method according to any one of embodiments 292-321, wherein the object is a human. (324) The method according to any one of embodiments 292-321, wherein the object is a non-human mammal. (325) The method according to embodiment 324, wherein the method is for veterinary applications. (326) The method according to any one of embodiments 292-325, wherein the delivery includes surgical implantation into the object.

[0298] A variety of different methods known in the art can be used to determine the Ki of any of the chimeric peptides described herein for binding to the target peptide and the carrier material (e.g., β-TCP). D Values. As non-limiting examples, these include electrophoretic mobility shift assays, filter binding assays, surface plasmon resonance assays, and biomolecular binding kinetics assays.

[0299] In some embodiments, the chimeric peptides provided herein are useful orthopedic materials and can be used as bone void fillers and for bone remodeling. In some embodiments, the chimeric peptides described herein are osteoconductive and readily reabsorbable.

[0300] connector In some cases, a pair of adjacent targeting peptides are directly adjacent to each other. In other cases, a pair of adjacent targeting peptides are separated by a linker sequence.

[0301] In some embodiments of the chimeric peptide comprising a targeting peptide and a therapeutic agent provided herein, the targeting peptide and the therapeutic agent are separated by a linker sequence. In some embodiments, the linker sequence is present between the two targeting peptides and / or between the targeting peptide and the therapeutic agent. In some cases, the therapeutic agent comprises a mammalian growth factor, such as BMP-2 comprising SEQ ID NO: 32. In some cases, the targeting peptide comprises one or more sequences from Table B. In some embodiments of the chimeric peptide comprising a linker located between the targeting peptide and the therapeutic agent, the presence of the linker increases the solubility of the chimeric peptide compared to a chimeric peptide without a linker. In some embodiments, the sequence and / or length of the linker is optimized. In some embodiments, the chimeric peptide comprising the linker is more soluble than the chimeric peptide without the linker. In some embodiments, the therapeutic agent in the chimeric peptide comprising the linker is more bioavailable than when there is no linker.

[0302] In some embodiments, the linker comprises a sequence of about 5 to about 50 amino acids. In some embodiments, the linker is a flexible linker, wherein at least about five of the amino acids do not have a regular secondary structure. In some embodiments, the regular secondary structure includes any helical structure, such as an α-helix or a 3-helix. 10 The linker may contain helices or π-helices, β-turns, ω-loops, and / or β-sheets. In some embodiments, the linker comprises at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% glycine, alanine, serine, glycine and alanine, glycine and serine, alanine and serine, or glycine, alanine, and serine. In some embodiments, the linker comprises at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% combinations of alanine, serine, glycine, and threonine. In some embodiments, the linker comprises 1, 2, 3, 4, or 5 sequences having the sequence GSEG (SEQ ID NO: 702). In some embodiments, the linker comprises 1, 2, 3, 4, or 5 sequences having the seq...

Claims

1. A polypeptide composition comprising: a targeting polypeptide comprising a sequence having at least 80% identity with SEQ ID NO: 22 (LLADTTHHRPWTVIGESTHHRPWS IIGESSHHKPFT GLGDTTHHRPWG ILAESTHHKPWT); and a therapeutic polypeptide comprising a sequence having at least 80% identity with a sequence selected from SEQ ID NO: 32, 46-71, 73-77, 79-101, 152, 168, 176, 268.

2. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 551 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 22 (LLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWT).

3. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 639 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 2 (VIGESTHHRPWS).

4. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 519 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 6 (IIGESSHHKPFT).

5. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 521 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 7 (GLGDTTHHRPWG).

6. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO: 515 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), wherein the polypeptide composition comprises X, and X comprises SEQ ID NO: 4 (ILAESTHHKPWT).

7. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO:

501.

8. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO:

507.

9. A polypeptide composition comprising a sequence having at least about 80% identity with SEQ ID NO:

506.

10. A method of delivering a therapeutic agent to an organ or tissue of a subject, the method comprising delivering a carrier material and the therapeutic agent to the organ or tissue, wherein the therapeutic agent is bound to the carrier material via a targeting peptide comprising: (a) A sequence having at least 80% identity with SEQ ID NO: 22, (b) A sequence having at least 80% identity with SEQ ID NO: 402, (c) A sequence having at least 80% identity with SEQ ID NO: 401, (d) A sequence having at least 80% identity with SEQ ID NO: 413 ((X1)(X2)), wherein X1 comprises SEQ ID NO: 1, and X2 comprises SEQ ID NO: 2 and SEQ ID NO:

6. (e) A sequence having at least 80% identity with SEQ ID NO:

21. (f) A sequence having at least 80% identity with SEQ ID NO: 414 ((X1)(X2)), wherein X1 comprises SEQ ID NO: 2, and X2 comprises SEQ ID NO: 6 and SEQ ID NO:

7. (g) A sequence having at least 80% identity with SEQ ID NO: 416 ((X1)(X2)), wherein X1 comprises SEQ ID NO: 6, and X2 comprises SEQ ID NO: 7 and SEQ ID NO:

4. (h) A sequence having at least 80% identity with SEQ ID NO: 408 ((X1)(X2)), wherein X1 comprises SEQ ID NO: 1 and X2 comprises SEQ ID NO:

2. (i) A sequence having at least 80% identity with SEQ ID NO: 20, (j) A sequence having at least 80% identity with SEQ ID NO: 409 ((X1)(X2)), wherein X1 comprises SEQ ID NO: 2 and X2 comprises SEQ ID NO:

6. (k) A sequence having at least 80% identity with SEQ ID NO: 411 ((X1)(X2)), wherein X1 contains SEQ ID NO: 6 and X2 contains SEQ ID NO:

7. (l) A sequence having at least 80% identity with SEQ ID NO: 412 ((X1)(X2)), wherein X1 comprises SEQ ID NO: 7 and X2 comprises SEQ ID NO:

4. (m) is a sequence that has at least 80% identity with SEQ ID NO: 2 (VIGESTHHRPWS). (n) is a sequence that has at least 80% identity with SEQ ID NO: 4 (ILAESTHHKPWT). (o) A sequence that has at least 80% identity with SEQ ID NO: 6 (IIGESSHHKPFT). (p) A sequence having at least 80% identity with SEQ ID NO: 7 (GLGDTTHHRPWG), or Any combination of two or more of (q) (a) to (p).

Images